<http://webisa.webdatacommons.org/422199986>	<http://www.w3.org/1999/02/22-rdf-syntax-ns#type>	<http://www.w3.org/ns/prov#Entity> .
<http://webisa.webdatacommons.org/422199986>	<http://www.w3.org/ns/prov#value>	"uture periods, the expected ability of Regulus to undertake certain activities and accomplish certain goals (including with respect to development and other activities related to RG-012 and RG-101 and with respect to the nomination of a third microRNA candidate for clinical development), the projected ti" .
<http://webisa.webdatacommons.org/422199986>	<http://www.w3.org/ns/prov#wasQuotedFrom>	<prnewswire.com> .
<http://webisa.webdatacommons.org/prov/462636299>	<http://www.w3.org/ns/prov#wasDerivedFrom>	<http://webisa.webdatacommons.org/422199986> .